Data from Pharmawand - Curated by EPG Health - Date added 12 January 2018

The National Institute for Health and Care Excellence (NICE) has, in its guidelines, recommended Simponi (golimumab) from Merck Inc., as a treatment for ankylosing spondylitis in adults whose disease has responded inadequately to Non-steroidal anti-inflammatory drugs (NSAIDS) or adults who cannot tolerate NSAIDS. NICE has recommended, in the past, Humira (adalimumab), Enbrel ( etanercept) and Cimzia (certolizumab pegol) for the condition and has stipulated that the cheapest of these therapies will be selected to treat the condition .

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Psoriasis

Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more.

+ 2 more

IL-17A in Psoriasis

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress.

+ 1 more

Load more

Related Content